Research programme: cancer therapeutics - Cancer Research Technology/Galapagos
Latest Information Update: 30 May 2007
At a glance
- Originator Cancer Research Technology
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 21 May 2007 The collaboration between Cancer Research Technology and Galapagos has been extended
- 19 Jan 2006 Preclinical trials in Cancer in United Kingdom (unspecified route)